Insulet Corporation $PODD Shares Sold by Segall Bryant & Hamill LLC

Segall Bryant & Hamill LLC lowered its stake in Insulet Corporation (NASDAQ:PODD) by 16.5% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 83,769 shares of the medical instruments supplier’s stock after selling 16,537 shares during the period. Segall Bryant & Hamill LLC’s holdings in Insulet were worth $17,578,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Larson Financial Group LLC boosted its stake in shares of Insulet by 114.6% during the 4th quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock worth $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Insulet during the fourth quarter worth $26,000. DV Equities LLC acquired a new stake in shares of Insulet during the fourth quarter worth $28,000. Elyxium Wealth LLC acquired a new stake in shares of Insulet during the fourth quarter worth $28,000. Finally, Mcguire Capital Advisors Inc. purchased a new stake in shares of Insulet during the fourth quarter valued at $29,000.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: UBS Group began research coverage of Insulet, potentially increasing institutional visibility and investor attention. However, the available report does not disclose UBS’s rating or price target. Insulet research coverage started at UBS Group
• Neutral Sentiment: The legal notices concern alleged violations of federal securities laws by Insulet and certain executives. The allegations have not been proven, and the financial impact of the litigation remains uncertain. Bronstein Gewirtz Grossman class action announcement
• Negative Sentiment: Several firms, including Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Bleichmar Fonti & Auld, Schall Brown & Schwartz, DJS Law Group, Rosen Law Firm, and Glancy Prongay, publicized the pending class action. The notices generally cover investors who purchased Insulet securities between February 21 or May 21, 2025, and May 26, 2026, and allege investor losses related to disclosures involving defective Omnipod manufacturing controls. Bleichmar Fonti & Auld securities lawsuit notice
• Negative Sentiment: The concentration of similar legal announcements may amplify concerns about potential damages, management accountability, regulatory scrutiny, and reputational risk, even though no judgment or settlement has been reported. Insulet investor alert from Schall Brown & Schwartz

Insulet Trading Down 0.2%

NASDAQ:PODD opened at $165.35 on Friday. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81. Insulet Corporation has a fifty-two week low of $138.79 and a fifty-two week high of $354.88. The stock’s 50-day moving average is $155.26 and its two-hundred day moving average is $198.24. The stock has a market cap of $11.45 billion, a PE ratio of 38.45, a price-to-earnings-growth ratio of 1.15 and a beta of 1.11.

Insulet (NASDAQ:PODD) last issued its earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, equities research analysts forecast that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Timothy C. Stonesifer acquired 2,790 shares of the company’s stock in a transaction on Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on PODD shares. Leerink Partners decreased their price target on Insulet from $360.00 to $247.00 in a research report on Thursday, May 7th. Oppenheimer cut their price objective on Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. UBS Group cut shares of Insulet from a “buy” rating to a “neutral” rating and set a $174.00 target price for the company. in a report on Tuesday. Bank of America decreased their target price on shares of Insulet from $288.00 to $208.00 and set a “buy” rating for the company in a report on Monday, May 18th. Finally, Citigroup lifted their target price on shares of Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and a consensus target price of $233.38.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.